# US Biosimilar Contract Manufacturing Market

> US Biosimilar Contract Manufacturing Market Research Report: Size, Share, Trend Analysis By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Applications (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.9%
- **2024:** $ 1,236.58 Million
- **2025:** $ 1,470.29 Million
- **2035:** $ 8,304.32 Million
- **Key Players:** Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US)

**Report ID:** MRFR/Pharma/17404-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biosimilar-contract-manufacturing-market-18950

---

## Market Summary

## **US Biosimilar Contract Manufacturing Market Overview**

As per MRFR analysis, the US Biosimilar Contract Manufacturing Market Size was estimated at 1.82 (USD Billion) in 2023. The US Biosimilar Contract Manufacturing Market Industry is expected to grow from 2.2(USD Billion) in 2024 to 14.5 (USD Billion) by 2035. The US Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 18.7% during the forecast period (2025 - 2035).

### **Key US Biosimilar Contract Manufacturing Market Trends Highlighted**

The US Biosimilar Contract Manufacturing Market is witnessing several significant trends driven by the increasing acceptance of biosimilars among healthcare providers and patients. This acceptance is largely fueled by the need for cost-effective alternatives to expensive biologics, which has led to growth in the number of biosimilars receiving regulatory approval from the FDA. Additionally, various initiatives by the US government focused on promoting competition in the pharmaceutical sector are encouraging greater investment in biosimilar manufacturing capabilities. This is creating opportunities for contract manufacturers to expand their services and enhance production capacity to meet rising demand.

Furthermore, there is an emerging trend of collaboration between biosimilar developers and CMOs (Contract Manufacturing Organizations), aimed at bolstering the supply chain and ensuring high-quality production. As the regulatory landscape evolves, companies are increasingly seeking partnerships that can offer expertise in navigating complex approval processes, allowing for more efficient time-to-market for biosimilars. In recent times, with the growing focus on personalized medicine, manufacturers are also exploring opportunities in the development of tailor-made biosimilar solutions, appealing to niche markets within the broader healthcare landscape.

The shift towards sustainability in manufacturing processes is also becoming prominent, as stakeholders are more focused on environmentally friendly production methods. With these trends, the US Biosimilar Contract Manufacturing Market is positioned for dynamic growth, driven by innovation, strategic partnerships, and an overall commitment to enhancing patient access to affordable medication alternatives.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

## **US Biosimilar Contract Manufacturing Market Drivers**

### **Growing Demand for Cost-Effective Biologics**

The rising demand for cost-effective biologics in the US is a significant driver for the US Biosimilar Contract Manufacturing Market Industry. With the increasing burden of healthcare costs, especially for chronic diseases, patients and healthcare providers are actively seeking alternatives that can reduce expenses. According to the Centers for Medicare & Medicaid Services, United States healthcare spending is projected to reach approximately USD 6.2 trillion by 2028, indicating a dire need for cost-effective solutions.

Furthermore, the introduction of biosimilars can reduce drug expenditures by approximately 30% to 50%, as noted in various studies. Major pharmaceutical companies, such as Amgen and Pfizer, are investing heavily in the production of biosimilars, which is expected to further accelerate market growth. By leveraging these opportunities, the US Biosimilar Contract Manufacturing Market industry is likely to witness substantial growth in the coming years.

### **Regulatory Support for Biosimilars**

Regulatory bodies in the US, such as the Food and Drug Administration, are increasingly providing support for the development and approval of biosimilars. This favorable regulatory environment is a prominent driver of growth within the US [Biosimilar Contract Manufacturing Market](../../../reports/biosimilar-contract-manufacturing-market-11903) Industry. The FDA has implemented streamlined pathways for biosimilar approvals, as well as clear guidelines for demonstrating biosimilarity. As of now, around 30 biosimilars have received approval since the introduction of the Biologics Price Competition and Innovation Act in 2010, indicating the responsiveness of the regulatory framework.

This regulatory support has encouraged many companies to invest in biosimilar development, thereby catalyzing the growth of the contract manufacturing landscape in the US.

### **Increase in Chronic Diseases and Aging Population**

The rising incidence of chronic diseases and an aging population in the US serve as vital drivers for the US Biosimilar Contract Manufacturing Market Industry. According to the National Council on Aging, approximately 80% of older adults in the US have at least one chronic disease, contributing to an overall shift towards biologic therapies. As the aging populace demands more biologics for treating age-related conditions such as diabetes and cancer, the need for biosimilar options to meet this demand becomes critical.

The American Cancer Society has also highlighted that cancer is expected to affect approximately 1 in 3 individuals in their lifetime, further emphasizing the need for affordable treatment options. The increase in chronic disease prevalence and the aging demographic are pivotal factors propelling the adoption of biosimilars and fostering growth in contract manufacturing within the US.

## **US Biosimilar Contract Manufacturing Market Segment Insights**

### **Biosimilar Contract Manufacturing Market Product Insights**

The US Biosimilar Contract Manufacturing Market, a crucial domain within the pharmaceutical industry, is experiencing exponential growth driven by the increasing demand for cost-effective biologics. This market is characterized by its focus on various products, particularly Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins. Recombinant Non-glycosylated Proteins play a vital role in therapeutic applications, often utilized in treatments for conditions such as cancer and autoimmune diseases. These proteins, typically produced using prokaryotic systems, have gained recognition for their consistency and ease of manufacturing, making them significant contributors to the market.

Meanwhile, Recombinant Glycosylated Proteins, which are essential for proper biological functions and interactions, are produced using eukaryotic systems that enable more complex structures and post-translational modifications. This segment addresses the growing needs for innovative therapeutic solutions, particularly in the realms of biopharmaceuticals and personalized medicine. Both product categories are influenced by key market trends such as the shift towards biosimilars due to their potential for cost savings compared to original biologics. The increasing incidence of chronic diseases in the US further fuels the demand for these products, presenting vast opportunities for growth and development in contract manufacturing capabilities.

The regulatory landscape also plays a pivotal role, as the US Food and Drug Administration has established pathways for the approval of biosimilars, thereby encouraging competition and novel approaches within the market. However, challenges like ensuring quality and compliance standards in production processes remain critical, driving manufacturers to invest in advanced technologies and stringent quality control measures. Overall, the focus on Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins highlights the importance of enhancing manufacturing efficiencies and leveraging scientific advancements to meet the evolving demands of healthcare markets across the United States.

This sector is poised for significant transformations, supported by a robust framework encouraging the development of biosimilars that can address the complexities of patient care and treatment accessibility.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

### **Biosimilar Contract Manufacturing Market Production Technology Insights**

The Production Technology segment within the US Biosimilar Contract Manufacturing Market is crucial for the growth of this industry as it significantly impacts the overall supply chain efficiency and product quality. This segment encompasses various methodologies, including both Mammalian and Non-Mammalian approaches, which cater to diverse biopharmaceutical needs. The Mammalian processes are known for their complex post-translational modifications, which are essential for the functionality of therapeutic proteins, making them vital for the development of highly effective biosimilars.

In contrast, Non-Mammalian systems, often utilizing microbial systems like yeast and bacteria, provide faster production times and lower costs, making them appealing for high-volume manufacturing. This diversification in production technology is particularly beneficial in the US, where regulatory frameworks encourage innovation while ensuring rigorous quality standards. The rising demand for affordable biologics and government initiatives supporting biosimilar development further enhance the significance of innovative production technologies in this market.

In summary, the integration of both Mammalian and Non-Mammalian technologies facilitates adaptability and responsiveness to market needs, thus driving the overall progress of the US Biosimilar Contract Manufacturing Market.

### **Biosimilar Contract Manufacturing Market Application Insights**

The Application segment of the US Biosimilar Contract Manufacturing Market plays a vital role in providing cost-effective and efficient biopharmaceutical solutions. This segment addresses various therapeutic areas including Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, and Rheumatoid Arthritis, among others. Oncology remains a critical focus area due to the rising incidence of cancer, necessitating innovative treatment options. Blood Disorders, which include conditions like hemophilia, are also significant as they require continuous and effective management.

Moreover, Growth Hormonal Deficiency and Chronic and Autoimmune Disorders present opportunities, given the increasing prevalence of these conditions in the aging population of the US. Rheumatoid Arthritis, as a widespread autoimmune condition, underscores the demand for biosimilars that can offer similar efficacy at a reduced cost. The segment's diversification into these areas highlights its importance in addressing unmet medical needs and improving patient access to essential medications. As the market evolves, advancements in technology and increased regulatory support at the federal level further bolster growth in this vital sector.

Together, these factors create a dynamic landscape for the US Biosimilar Contract Manufacturing Market, enhancing overall market data and statistics, while promoting sustainable market growth.

## **US Biosimilar Contract Manufacturing Market Key Players and Competitive Insights**

The US Biosimilar Contract Manufacturing Market is characterized by a complex and evolving landscape, with increasing focus on the development and production of biosimilar products aimed at improving patient access to essential medicines while reducing overall healthcare costs. This market has attracted considerable attention due to the growing acceptance of biosimilars among healthcare professionals and regulatory agencies, leading to a surge in demand for contract manufacturing services that cater to this specific segment. Competition within the market is fueled by the entry of numerous players, each vying for partnerships with established pharmaceutical companies.

The dynamics of this market are influenced by factors such as technological advancements, regulatory challenges, and the need for robust quality assurance processes, all of which determine the operational capability and market reach of contract manufacturers.

Teva Pharmaceutical Industries, a prominent player in the US Biosimilar Contract Manufacturing Market, has established a strong foothold through its extensive portfolio of biosimilar products. The company benefits from a well-developed infrastructure that supports large-scale manufacturing processes tailored for biosimilars, allowing Teva to deliver high-quality and competitively priced products to the market. Teva’s commitment to innovation is evident in its efforts to enhance manufacturing technologies and processes, which also accounts for its agility in responding to market demands.

Additionally, the company's established relationships with healthcare providers and payers bolster its competitive position, ensuring greater market access and a strong reputation for reliability in biosimilar manufacturing.

Samsung Biologics is another key player in the US Biosimilar Contract Manufacturing Market, renowned for its state-of-the-art biomanufacturing facilities and comprehensive service offerings. The company provides a wide range of services including cell line development, process development, and comprehensive manufacturing solutions that ensure timely delivery of high-quality biosimilars. Samsung Biologics has made significant investments in expanding its operational capacity, ensuring it remains flexible and responsive to the unique demands of the biosimilar space. Additionally, strategic collaborations and partnerships with various pharmaceutical companies have enhanced its market presence and operational capabilities in the US.

Through its commitment to innovation and quality, Samsung Biologics aims to be a leader in the biopharmaceutical contract manufacturing space, further solidifying its position by leveraging advanced technologies and maintaining a strong focus on regulatory compliance and customer satisfaction.

### **Key Companies in the US Biosimilar Contract Manufacturing Market Include**

- Teva Pharmaceutical Industries
- Samsung Biologics
- Lonza
- Sandoz
- **[BristolMyers Squibb](https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Completes-Sale-of-Manufacturing-Facility-in-Syracuse-New-York/default.aspx)**
- Eli Lilly and Company
- Boehringer Ingelheim
- Fujifilm Diosynth Biotechnologies
- Catalent
- Pfizer
- Generium
- Amgen
- AbbVie
- Roche
- Mylan

## **US Biosimilar Contract Manufacturing Market Industry Developments**

Recent developments in the US Biosimilar Contract Manufacturing Market indicate significant activity among key players. Companies like Teva Pharmaceutical Industries, Samsung Biologics, and Lonza continue to expand their manufacturing capabilities to meet rising industry demand. Bristol-Myers Squibb and Eli Lilly and Company have actively engaged in partnerships aimed at enhancing their biosimilar pipelines, which were highlighted in the market earlier this year.

Notably, in September 2023, Catalent announced a major strategic collaboration with Amgen to bolster its biosimilar production capabilities, demonstrating a commitment to addressing the growing need for affordable biologic medicines. Similarly, Pfizer and Boehringer Ingelheim each reported advancements in their respective manufacturing processes, with a focus on increasing efficiency and compliance with regulatory standards.

Additionally, the US government's initiatives to support the biosimilars market have catalyzed a competitive landscape, affecting valuations and investment strategies for companies like Roche and Mylan. Over the past two to three years, the market has witnessed an upward trend, with numerous investments aimed at strengthening production and reducing costs for biosimilar medications, aligning with ongoing healthcare reforms that emphasize affordability and access.

## **US Biosimilar Contract Manufacturing Market Segmentation Insights**

### **Biosimilar Contract Manufacturing Market Product Outlook**

- Recombinant Non-glycosylated Proteins
- Recombinant Glycosylated Proteins

### **Biosimilar Contract Manufacturing Market Production Technology Outlook**

- Mammalian
- Non-Mammalian

### **Biosimilar Contract Manufacturing Market Application Outlook**

- Oncology
- Blood Disorders
- Growth Hormonal Deficiency
- Chronic & Autoimmune Disorders
- Rheumatoid Arthritis
- Others

## Market Drivers

### Increasing Healthcare Expenditure

The rising healthcare expenditure in the US is a pivotal driver for the biosimilar contract-manufacturing market. As healthcare costs continue to escalate, stakeholders are increasingly seeking cost-effective alternatives to expensive biologics. In 2025, healthcare spending in the US is projected to reach approximately $4.3 trillion, with a significant portion allocated to biologics. This trend suggests that healthcare providers and payers are likely to favor biosimilars, which can offer similar therapeutic benefits at a reduced cost. Consequently, contract manufacturers specializing in biosimilars are positioned to benefit from this shift, as they provide essential services to meet the growing demand for affordable treatment options. The increasing focus on value-based care further emphasizes the need for cost-efficient solutions, thereby enhancing the prospects for the biosimilar contract-manufacturing market.

### Increased Focus on Personalized Medicine

The shift towards personalized medicine is emerging as a key driver for the biosimilar contract-manufacturing market. As healthcare evolves, there is a growing recognition of the need for tailored treatment approaches that cater to individual patient profiles. Biosimilars, with their ability to mimic complex biologics, are well-suited to support this trend. In 2025, the market for personalized medicine is expected to reach $2.5 trillion, underscoring the potential for biosimilars to play a significant role in this paradigm shift. Contract manufacturers that specialize in biosimilars are likely to find new opportunities as healthcare providers increasingly seek to incorporate these products into personalized treatment plans. The alignment of biosimilars with the principles of personalized medicine may enhance their acceptance and utilization, thereby driving growth in the biosimilar contract-manufacturing market.

### Advancements in Biomanufacturing Technologies

Technological advancements in biomanufacturing are transforming the landscape of the biosimilar contract-manufacturing market. Innovations such as single-use bioreactors and continuous manufacturing processes are enhancing production efficiency and reducing costs. These advancements enable contract manufacturers to produce biosimilars at a larger scale while maintaining quality and compliance with regulatory standards. In 2025, the market for biomanufacturing technologies is projected to grow by approximately 15%, reflecting the increasing adoption of these innovations. As manufacturers leverage cutting-edge technologies, they can respond more effectively to the rising demand for biosimilars, thereby positioning themselves competitively within the market. The integration of advanced manufacturing techniques is likely to play a pivotal role in the growth trajectory of the biosimilar contract-manufacturing market.

### Growing Patient Population with Chronic Diseases

The increasing prevalence of chronic diseases in the US is a significant driver for the biosimilar contract-manufacturing market. As the population ages and lifestyle-related health issues become more common, the demand for biologic therapies is expected to rise. In 2025, it is estimated that nearly 60% of adults in the US will be living with at least one chronic condition, such as diabetes or arthritis. This surge in patient numbers necessitates the availability of effective and affordable treatment options, which biosimilars can provide. Contract manufacturers are thus likely to see heightened demand for their services as healthcare providers seek to incorporate biosimilars into treatment regimens. The biosimilar contract-manufacturing market is poised to expand as it addresses the needs of a growing patient population requiring ongoing care and management of chronic diseases.

### Regulatory Support and Streamlined Approval Processes

Regulatory support plays a crucial role in shaping the biosimilar contract-manufacturing market. The US Food and Drug Administration (FDA) has implemented guidelines that facilitate the approval of biosimilars, thereby encouraging manufacturers to invest in this sector. The introduction of the Biologics Control Act and subsequent amendments have streamlined the pathway for biosimilar approvals, reducing the time and cost associated with bringing these products to market. As of 2025, the FDA has approved over 40 biosimilars, indicating a growing acceptance of these products within the healthcare system. This regulatory environment not only fosters innovation but also instills confidence among stakeholders, which is likely to drive demand for contract manufacturing services in the biosimilar sector. The supportive framework provided by regulatory bodies is essential for the sustained growth of the biosimilar contract-manufacturing market.

## Future Outlook

The [Biosimilar Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903) is projected to grow at 18.9% CAGR from 2025 to 2035, driven by increasing demand for cost-effective biologics and regulatory support.

**New opportunities:**

- Expansion of manufacturing capabilities for complex biosimilars Strategic partnerships with biotech firms for co-development Investment in advanced bioprocessing technologies to enhance efficiency

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in biopharmaceutical manufacturing.

## Segment Insights

### By Product: Recombinant Glycosylated Proteins (Largest) vs. Recombinant Non-glycosylated Proteins (Fastest-Growing)

In the US biosimilar contract-manufacturing market, Recombinant Glycosylated Proteins hold a significant share, dominating the market landscape. This segment's robust presence is attributed to its essential applications in therapeutic areas such as oncology and autoimmune conditions. In contrast, Recombinant Non-glycosylated Proteins represent a rapidly emerging field, gaining traction owing to advancements in manufacturing technologies and process efficiencies.

The growth trends in these segments reveal a competitive landscape driven by innovation and demand for personalized medicine. Market players are focusing on enhancing their capabilities to produce high-quality biosimilars, particularly in the Recombinant Non-glycosylated Proteins segment, which is expected to witness a surge in demand. Factors such as regulatory support and the increasing prevalence of chronic diseases are contributing to this dynamic growth.

Recombinant Glycosylated Proteins (Dominant) vs. Recombinant Non-glycosylated Proteins (Emerging)

Recombinant Glycosylated Proteins are well-established in the US biosimilar contract-manufacturing market, primarily due to their complex manufacturing processes and higher therapeutic efficacy. These proteins are pivotal in various therapeutic applications, leading to their dominance in market share. Conversely, Recombinant Non-glycosylated Proteins are emerging as a crucial player, benefitting from innovations that streamline their production. They are increasingly recognized for their cost-effectiveness and versatility in drug formulation. This growing segment is anticipated to create new opportunities within the market as manufacturers seek to expand their portfolios and enhance efficiencies.

### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing)

In the US biosimilar contract-manufacturing market, the production technology segment is primarily dominated by mammalian systems, which have established a strong market presence given their ability to produce complex biologics that closely mimic human proteins. This segment holds the largest share due to the widespread acceptance of products derived from mammalian cell cultures, as well as advancements in bioprocessing technologies that enhance yield and quality standards.

Conversely, non-mammalian production technologies, such as microbial systems, are rapidly gaining traction. These systems are recognized for their faster production times and lower operational costs, making them increasingly attractive for manufacturers. The growth of the non-mammalian segment is driven by innovations in microbial fermentation processes and the rising demand for cost-effective biosimilars, positioning it as the fastest-growing segment in the market.

Production Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging)

Mammalian production technology is the dominant method employed in the US biosimilar contract-manufacturing market, primarily due to its ability to effectively produce intricate biologics, including monoclonal antibodies and therapeutic proteins. This technology leverages human cell lines, ensuring high-quality product functionality and regulatory compliance. In contrast, non-mammalian production technology, while emerging, thrives on microbial systems which offer a competitive edge in speed and cost-effectiveness. This segment appeals to manufacturers focusing on rapid delivery and budget-friendly solutions, with continuous updates in process optimization allowing non-mammalian systems to adapt swiftly to market demands.

### By Application: Oncology (Largest) vs. Chronic & Autoimmune Disorders (Fastest-Growing)

In the US biosimilar contract-manufacturing market, the oncology segment represents the largest share of the application market, driven by high demand for cancer therapies and substantial investments in biotech innovations. Following closely, the chronic and autoimmune disorders segment has gained significant traction, fueled by increasing awareness of autoimmune diseases and the rising need for cost-effective therapies that biosimilars can provide.

Growth trends in this segment are largely influenced by advancements in biopharmaceutical technologies and an expanding patient base requiring effective treatment options. Innovations in biosimilar formulations and regulatory approvals are pivotal drivers enhancing the competitiveness of these therapies. The growing emphasis on healthcare cost reduction and accessibility also propels the chronic and autoimmune disorders segment to emerge as a critical player in the market.

Oncology: Dominant vs. Chronic & Autoimmune Disorders: Emerging

The oncology segment stands out as the dominant force in the US biosimilar contract-manufacturing market, characterized by its robust pipeline of biosimilar products aimed at various cancer treatments. With the prevalence of cancer being a major public health concern, this segment enjoys substantial market stability and investor interest. In contrast, chronic and autoimmune disorders represent an emerging segment, showcasing a rapid growth trajectory due to heightened focus on personalized medicine and tailored treatment protocols. As regulatory bodies streamline the approval process for biosimilars, this segment anticipates increased market penetration. Both segments reflect a proactive approach toward addressing unmet medical needs, fostering innovation, and ultimately improving patient outcomes.

## Competitive Benchmarking

The biosimilar contract-manufacturing market is characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the need for rapid market entry. Key players such as Samsung Biologics (KR), Lonza Group (CH), and Catalent (US) are strategically positioned to leverage their extensive manufacturing capabilities and technological expertise. Samsung Biologics (KR) focuses on expanding its production capacity, while Lonza Group (CH) emphasizes innovation through advanced bioprocessing technologies. Catalent (US) is enhancing its service offerings through strategic partnerships, which collectively shape a competitive environment that prioritizes efficiency and responsiveness to market needs.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure encourages collaboration and innovation, as firms seek to differentiate themselves through unique service offerings and technological advancements.
In October Lonza Group (CH) announced a strategic partnership with a leading biopharmaceutical company to co-develop a new biosimilar product. This collaboration is expected to enhance Lonza's capabilities in biomanufacturing and accelerate the product's time to market, reflecting a trend towards strategic alliances that bolster innovation and efficiency in the sector. Such partnerships may also facilitate knowledge sharing and resource optimization, further strengthening Lonza's competitive position.
In September Catalent (US) expanded its manufacturing facility in Indiana, investing approximately $50 million to enhance its biosimilar production capabilities. This expansion is indicative of Catalent's commitment to meeting the growing demand for biosimilars and underscores the importance of scaling operations to maintain competitive advantage. The investment not only increases production capacity but also positions Catalent to better serve its clients in a rapidly evolving market.
In August Samsung Biologics (KR) launched a new digital platform aimed at streamlining its manufacturing processes and improving operational efficiency. This initiative reflects a broader trend towards digital transformation within the industry, as companies seek to leverage technology to enhance productivity and reduce costs. By adopting advanced digital solutions, Samsung Biologics (KR) is likely to improve its responsiveness to client needs and strengthen its market position.
As of November current competitive trends in the biosimilar contract-manufacturing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into manufacturing processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as firms strive to meet the complex demands of the biosimilar market.

## Recent News & Developments

Recent developments in the US Biosimilar Contract Manufacturing Market indicate significant activity among key players. Companies like Teva Pharmaceutical Industries, Samsung Biologics, and Lonza continue to expand their manufacturing capabilities to meet rising industry demand. Bristol-Myers Squibb and Eli Lilly and Company have actively engaged in partnerships aimed at enhancing their biosimilar pipelines, which were highlighted in the market earlier this year.

Notably, in September 2023, Catalent announced a major strategic collaboration with Amgen to bolster its biosimilar production capabilities, demonstrating a commitment to addressing the growing need for affordable biologic medicines. Similarly, Pfizer and Boehringer Ingelheim each reported advancements in their respective manufacturing processes, with a focus on increasing efficiency and compliance with regulatory standards.

Additionally, the US government's initiatives to support the biosimilars market have catalyzed a competitive landscape, affecting valuations and investment strategies for companies like Roche and Mylan. Over the past two to three years, the market has witnessed an upward trend, with numerous investments aimed at strengthening production and reducing costs for biosimilar medications, aligning with ongoing healthcare reforms that emphasize affordability and access.

## Report Scope

| MARKET SIZE 2024 | 1236.58(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1470.29(USD Million) |
| MARKET SIZE 2035 | 8304.32(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) |
| Segments Covered | Product, Production Technology, Application |
| Key Market Opportunities | Growing demand for cost-effective biosimilars drives innovation in contract-manufacturing capabilities and technologies. |
| Key Market Dynamics | Rising demand for cost-effective biologics drives growth in biosimilar contract-manufacturing partnerships and innovation. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US biosimilar contract-manufacturing market?**
A: The market valuation was $1236.58 Million in 2024.

**Q: What is the projected market valuation for the US biosimilar contract-manufacturing market by 2035?**
A: The projected valuation for 2035 is $8304.32 Million.

**Q: What is the expected CAGR for the US biosimilar contract-manufacturing market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 18.9%.

**Q: Which companies are considered key players in the US biosimilar contract-manufacturing market?**
A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, and others.

**Q: What are the main product segments in the US biosimilar contract-manufacturing market?**
A: Main product segments include Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins.

**Q: What was the market size for Recombinant Glycosylated Proteins in 2024?**
A: The market size for Recombinant Glycosylated Proteins was $836.58 Million in 2024.

**Q: How does the production technology segment break down in the US biosimilar contract-manufacturing market?**
A: The segment includes Mammalian production at $800.0 Million and Non-Mammalian at $436.58 Million.

**Q: What applications are driving growth in the US biosimilar contract-manufacturing market?**
A: Key applications include Oncology, Blood Disorders, and Chronic & Autoimmune Disorders.

**Q: What was the market size for Oncology applications in 2024?**
A: The market size for Oncology applications was $200.0 Million in 2024.

**Q: What is the expected growth trajectory for Chronic & Autoimmune Disorders applications by 2035?**
A: The market for Chronic & Autoimmune Disorders is projected to reach $2000.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biosimilar-contract-manufacturing-market-18950*